Suchergebnisse - "Subbiah, Vivek"

PubPharm (26)

1

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer : Updated Efficacy and Safety Data from the ARROW Study

enthalten in: Thyroid : official journal of the American Thyroid Association | 2024

von Subbiah, V. | Hu, M. | Mansfield, A. | +21

ErratumIn: Thyroid. 2024 Apr 16;:. - PMID 38625021

2

Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers

enthalten in: Cell reports. Medicine | 2023

von Nardo, M. | Gouda, M. | Nelson, B. | +7

3

Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma : A Case Series

enthalten in: Clinical lung cancer | 2023

von Fricke, J. | Wang, J. | Gallego, N. | +7

4

RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond

enthalten in: Cancer research | 2023

von Wu, J. | Subbiah, V.

CommentOn: Cancer Res. 2023 Oct 2;83(19):3237-3251. - PMID 37071495

5

Exceptional Responses to Selpercatinib in RET Fusion-Driven Metastatic Pancreatic Cancer

enthalten in: JCO precision oncology | 2023

von Bhamidipati, D. | Yedururi, S. | Huse, J. | +3

6

Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care : an international mixed-method study

enthalten in: BMC medical education | 2023

von Lazure, P. | Sireci, A. | Subbiah, V. | +6

7

RET aberrant cancers and RET inhibitor therapies : Current state-of-the-art and future perspectives

enthalten in: Pharmacology & therapeutics | 2023

von Addeo, A. | Miranda-Morales, E. | den Hollander, P. | +5

8

Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer : A Case Series

enthalten in: Thyroid : official journal of the American Thyroid Association | 2023

von Contrera, K. | Gule-Monroe, M. | Hu, M. | +13

9

Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer : Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Drilon, A. | Subbiah, V. | Gautschi, O. | +15

CommentIn: J Clin Oncol. 2023 Jan 10;41(2):410-412. - PMID 36122320

10

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001) : a phase 1/2, open-label, basket trial

enthalten in: The Lancet. Oncology | 2022

von Subbiah, V. | Wolf, J. | Konda, B. | +12

CommentIn: Lancet Oncol. 2022 Oct;23(10):1235-1237. - PMID 36108663